Overview

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Corcept Therapeutics